Category: B
Butador 10mg/ml Solution for Injection for Horses, Dogs & Cats is used as a pain relief solution. In horses, it can be used as a sedative, pre-anaesthetic and for the short-term relief of pain such as colic of gastrointestinal tract origin. In cats and dogs, it can also be used as a sedative and pre-anaesthetic and for relief of moderate visceral pain e.g. pre-and post-surgical as well as post-traumatic pain.
It's a clear, colourless to almost colourless solution and the excipient is Benzethonium chloride 0.1 mg. The active ingredient is Butorphanol and 1 ml contains Butorphanol 10mg (as butorphanol tartrate 14.58 mg).
Butador 10mg/ml Solution is a prescription-only medication. This means that before you complete your purchase, you are required to upload a prescription through our online portal.
Once our team has confirmed you've ordered the right medication for your horse, cat or dog, we will send out your order. It's a simple process that means you can buy Butador online instead of going to your vet every month.
Butador 10mg/ml Solution for Injection is given intramuscularly or subcutaneously.
Horse: Intravenous use
Dog: Intravenous, subcutaneous and intramuscular use
Cat: Intravenous and subcutaneous use
The shelf-life after first opening the immediate container is 28 days. Do not use it after the expiry date stated on the label.
The safety of the product in puppies, kittens and foals has not been established. Use of the product in these groups should be on the basis of a risk-benefit analysis by the responsible veterinarian.
Due to its antitussive properties, butorphanol may lead to an accumulation of mucous in the respiratory tract. Therefore, in animals with respiratory diseases associated with increased mucous production, butorphaol should only be used after a risk-benefit evaluation by the responsible veterinarian. If respiratory depression occurs, naloxone may be used as an antidote.
Sedation may be noted in treated animals. The combination of butorphanol and α2-adrenoceptor agonists should be used with caution in animals with cardiovascular disease. The concurrent use of anticholinergic drugs e.g atropine should be considered.
Administration of butorphanol and romifidine in one syringe should be avoided due to increased bradycardia, heart block and ataxia.
The use of the product at the recommended dose may lead to transient ataxia and/or excitement. Therefore, to prevent injuries in patients and people when treating horses, the location for the treatment should be chosen carefully.
Cats should be weighed to ensure that the correct dose is calculated. An appropriate graduated syringe must be used to allow accurate administration of the required dose volume (e.g. insulin syringe or 1 ml graduated syringe). If repeated administrations are required, use different injection sites.
As a sedative: In combination with α2-adrenoceptor agonists (medetomidine).
As a pre-anaesthetic: Part of anaesthetic regime (medetomidine, ketamine).
Royal Mail 2nd Class / Parcel Force 48
UK to UK :Normally arrives in 2-4 business days.
UK to Ireland :Normally arrives in 4-6 business days
UK to EU Countries : Normally arrives in 6-10 working days depending on where the parcel is going
Please note standered delivery is none trackable , none insured , no responsabily for lose or Damage
----------------------------------------------------------------------------------------------------------------
Royal Mail First Class / Parcel Force 24
UK to UK :Normally arrives in 1-2 business days.
UK to Ireland 3-4 business days
UK to EU Countries : Normally arrives in 6-10 working days depending on where the parcel is going
Please note :Trackable , Royal Mail insured up to £50.
--------------------------------------------------------------------------------------------------------
Parcel Force Express AM Guaranteed before Midday.
UK to UK only . UP to 5KG Max Weight
Arrives next day before 12 noon, requires a signature.
Parcel Forcel Terms & Conditions apply
Important: Parcel Force advise that there are some postcodes where an extended delivery time exists, and may affect the date of delivery or the service is not available.
| Category | POM-V |
| Temperature | Ambient |
| MA/VM/EU No: | 22080/4002 |
| Species |
|
| VMD Link | Product Information Database (defra.gov.uk) |
| NOAH Link | https://www.noahcompendium.co.uk/?id=-449056 |
| Dosage | Horse: Intravenous use Dog: Intravenous, subcutaneous and intramuscular use Cat: Intravenous and subcutaneous use HORSE As an analgesic Monotherapy: 0.1 mg/kg (1 ml/100 kg bw) IV. As a sedative and as a pre-anaesthetic With detomidine: Detomidine: 0.012 mg/kg IV, followed within 5 minutes by Butorphanol: 0.025 mg/kg (0.25 ml /100 kg bw) IV. With romifidine: Romifidine: 0.05 mg/kg IV, followed within 5 minutes by Butorphanol: 0.02 mg/kg (0.2 ml/100 kg bw) IV. With xylazine: Xylazine: 0.5 mg/kg IV, followed after 3-5 minutes by Butorphanol: 0.05–0.1 mg/kg (0.5-1 ml/100 kg bw) IV. DOG As an analgesic Monotherapy: 0.1 - 0.4 mg/kg (0.01 – 0.04 ml/kg bw) slowly IV (in the lower to medium dose range) as well as IM, SC. For post-operative pain control the injection should be administered 15 minutes before the end of anaesthesia in order to achieve sufficient pain relief during the recovery phase. As a sedative With medetomidine: Butorphanol: 0.1 mg/kg (0.01 ml/kg bw) IV, IM Medetomidine: 0.01 mg/kg IV, IM. As a pre-anaesthetic With medetomidine and ketamine: Butorphanol: 0.1 mg/kg (0.01 ml/kg bw) IM Medetomidine: 0.025 mg/kg IM, followed after 15 minutes by Ketamine: 5 mg/kg IM. It is only possible to use atipamezole 0.1 mg/kg body weight for medetomidine-antagonisation when ketamine action has ceased. CAT As an analgesic Monotherapy: 15 minutes prior to recovery either: 0.4 mg/kg (0.04 ml/kg bw) SC or: 0.1 mg/kg (0.01 ml/kg bw) IV As a sedative With medetomidine: Butorphanol: 0.4 mg/kg (0.04 ml/kg bw) SC Medetomidine: 0.05 mg/kg SC. For wound debridement an additional local anaesthesia is recommended. Medetomidine-antagonisation is possible with atipamezole 0.125 mg/kg body weight. As a pre-anaesthetic With medetomidine and ketamine: Butorphanol: 0.1 mg/kg (0.01 ml/kg bw) IV Medetomidine: 0.04 mg/kg IV Ketamine: 1.5 mg/kg IV. It is only possible to use atipamezole 0.1 mg/kg body weight for medetomidine–antagonisation when ketamine action has ceased. Butorphanol is intended for use where short (horse and dog) and short to medium (cat) analgesia is required. The dose may be repeated as required. The need for and timing of repeated treatment will be based on clinical response. For information on the duration of analgesia see section “Further information”. Rapid intravenous injection should be avoided. Do not mix the product with other veterinary medicinal products in one syringe. Contra-indications, warnings, etc Do not use in case of hypersensitivity to the active substance or to any of the excipients. Do not use for treatment of animals with severe dysfunction of the liver and kidneys, in case of cerebral injury or organic brain lesions and in animals with obstructive respiratory diseases, heart dysfunctions or spastic conditions. For combination use with ?2-agonists in horses: Do not use in horses with a pre-existing cardiac dysrhythmia. The combination will cause a reduction in gastrointestinal motility and consequently should not be used in cases of colic associated with impaction. Do not use combination during pregnancy. Adverse reaction HORSE Undesirable effects are generally related to the known activity of opioids. In published trials with butorphanol, transient ataxia, lasting about 3 to 15 minutes, occurred in about 20 % of horses. Mild sedation occurred in about 10 % of horses. Increased motor activity (running movements) is possible. Gastrointestinal motility may be reduced. For combination use: Any reduction of gastrointestinal motility caused by butorphanol may be enhanced by the concomitant use of ?2-agonists. The respiratory depressive effects of ?2-agonists may be enhanced by concomitant butorphanol, particularly if respiratory function is already impaired. Other undesirable effects (e.g. cardiovascular) are likely to be related to the ? 2-agonist. DOG/CAT Depression of the respiratory and cardiovascular system. Local pain associated with intramuscular administration. Decreased gastrointestinal motility. In rare cases, ataxia, anorexia and diarrhoea. In cats excitation or sedation, anxiety, disorientation, dysphoria and mydriasis are possible. If you notice any serious effects or other effects not mentioned in this leaflet, please inform your veterinary surgeon. Special warnings The precautionary measures required for contact with animals should be followed and stress factors for the animals should be avoided. In cats, individual response to butorphanol may be variable. In the absence of an adequate analgesic response, an alternative analgesic agent should be used. Increasing of the dose may not increase the intensity or duration of analgesia. Special precautions for use in animals The safety of the product in puppies, kitten and foals has not been established. Use of the product in these groups should be on the basis of a risk-benefit analysis by the responsible veterinarian. Due to its antitussive properties, butorphanol may lead to an accumulation of mucous in the respiratory tract. Therefore, in animals with respiratory diseases associated with increased mucous production, butorphaol should only be used after a risk-benefit evaluation by the responsible veterinarian. If respiratory depression occurs, naloxone may be used as an antidote. Sedation may be noted in treated animals. The combination of butorphanol and ?2-adrenoceptor agonists should be used with caution in animals with cardiovascular disease. The concurrent use of anticholinergic drugs e.g atropine should be considered. Administration of butorphanol and romifidine in one syringe should be avoided due to increased bradycardia, heart block and ataxia. HORSE The use of the product at the recommended dose may lead to transient ataxia and/or excitement. Therefore, to prevent injuries in patient and people when treating horses, the location for the treatment should be chosen carefully. CAT Cats should be weighed to ensure that the correct dose is calculated. An appropriate graduated syringe must be used to allow accurate administration of the required dose volume (e.g. insulin syringe or 1 ml graduated syringe). If repeated administrations are required, use different injection sites. Interaction with other medicinal products The concomitant administration of other drugs which are metabolised in the liver may enhance the effect of butorphanol. Butorphanol used with concurrently administered anaesthetics, centrally sedative or respiratory depressive drugs produces additive effects. Any use of butorphanol in this context requires acute control and a careful adaptation of the dose. Administration of butorphanol may remove the analgesic effect in animals, which have already received pure ?-opioid analgesics. Overdose HORSE Increased dosages could result in respiratory depression as a general opioid effect. Intravenous doses of 1.0 mg/kg (10 x the recommended dose), repeated at 4-hourly intervals for 2 days, led to transient adverse effects, including pyrexia, tachypnoea, CNS signs (hyperexcitability, restlessness, mild ataxia leading to somnolence) and gastrointestinal hypomotility, sometimes with abdominal discomfort. An opioid antagonist (e.g. Naloxone) may be used as an antidote. DOG/CAT Miosis (dog)/Mydriasis (cat), respiratory depression, hypotension, disorders of the cardiovascular system and in severe cases respiratory inhibition, shock and coma. Depending on the clinical situation counter-measures should be taken under intense medical monitoring. Monitoring is required for a minimum of 24 hours. Use during pregnancy and lactation Butorphanol crosses the placental barrier and penetrates into milk. Studies in laboratory species have not produced any evidence of teratogenic effects. The safety of this veterinary medicinal product has not been established in the target species during pregnancy and lactation. The use of butorphanol during pregnancy and lactation is not recommended. User warnings Butorphanol has opioid-like activity. Precautions should be taken to avoid accidental injection/self-injection with this potent drug. The most frequent adverse effects of butorphanol in humans are drowsiness, sweating, nausea, dizziness and vertigo and may occur following unintended self-injection. If accidental self-injection occurs, seek medical advice immediately and show the package leaflet or the label to the physician. Do not drive. An opioid antagonist (e.g. naloxone) may be used as an antidote. Wash splashes from skin and eyes immediately |
| Withdrawals |
